Advertisement


William G. Wierda, MD, PhD, on Updates to the Management of CLL

2015 NCCN Annual Conference

Advertisement

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.



Related Videos

Skin Cancer
Symptom Management

Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.

Lung Cancer

Thomas A. D’Amico, MD, on Diagnosis and Treatment of NSCLC Using Minimally Invasive Techniques

Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer surgeries in the United States, in 30% of procedures in Asia, and in as few as 10% to 20% of procedures in Europe.

Survivorship

Crystal S. Denlinger, MD, on Management of Anthracycline-Induced Cardiac Toxicity

Crystal S. Denlinger, MD, of Fox Chase Cancer Center, discusses cardiac toxicities in cancer survivors, a new topic for the NCCN Survivorship Guidelines this year, and the need for more research on this important side effect, including prevention and surveillance.

Breast Cancer

Amy Cyr, MD on Advances in Management of Early-Stage Breast Cancer

Amy Cyr, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, discusses advances made in the treatment of early-stage breast cancer: less radiation and a shorter course, the rising use of molecular profiling, and less invasive surgery and reduced amounts of surgery.

Skin Cancer

John A. Thompson, MD, on Treatment Options for Advanced Melanoma

John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembrolizumab, trametinib, nivolumab, and dabrafenib.

Advertisement

Advertisement




Advertisement